These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15500384)

  • 1. Review of tegaserod in the treatment of irritable bowel syndrome.
    Patel S; Berrada D; Lembo A
    Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
    Rivkin A
    Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
    Wagstaff AJ; Frampton JE; Croom KF
    Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of tegaserod in irritable bowel syndrome management.
    Berardi RR
    J Am Pharm Assoc (2003); 2004; 44(1):41-51. PubMed ID: 14965152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M
    Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM; Wagner A;
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G; Snape WJ; Otten MH; Earnest DL; Langaker KE; Pruitt RE; Pecher E; Nault B; Rojavin MA
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1701-8. PubMed ID: 12269961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod for the Treatment of Irritable Bowel Syndrome.
    Madia VN; Messore A; Saccoliti F; Tudino V; De Leo A; De Vita D; Bortolami M; Scipione L; Pindinello I; Costi R; Di Santo R
    Antiinflamm Antiallergy Agents Med Chem; 2020; 19(4):342-369. PubMed ID: 31518227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S
    Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL; Schoenfeld P
    Drug Saf; 2004; 27(9):619-31. PubMed ID: 15230644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome.
    Fried M; Beglinger C; Bobalj NG; Minor N; Coello N; Michetti P;
    Eur J Gastroenterol Hepatol; 2005 Apr; 17(4):421-7. PubMed ID: 15756094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tegaserod.
    Scott LJ; Perry CM
    Drugs; 1999 Sep; 58(3):491-6; discussion 497-8. PubMed ID: 10493276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
    Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.